AVBP
ArriVent BioPharma, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$31.16
+0.42%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.1x
Market Cap
$1.54B
MomentumView details →
1D Return
+0.42%
YTD Return
+53.40%
RSI (14)
52.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.1x
Market Cap
$1.54B
RSI (14)
52.4
MomentumView details →
1D Return
+0.42%
YTD Return
+53.40%
SummaryUpdated Jun 1, 2026
ArriVent BioPharma, Inc. (NASDAQ:AVBP) is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in Newtown Square, Pennsylvania. The company went public in January 2024 and focuses on developing targeted cancer therapies, particularly for non-small-cell lung cancer and other solid tumors. ArriVent operates in the highly specialized field of oncology drug development, with its lead asset being an advanced-stage cancer treatment currently in Phase 3 clinical trials.
Similar companies
Latest newsMore news →